Verma S, et al. - Researchers evaluated the efficacy of liraglutide in patients with type 2 diabetes mellitus with and without a history of myocardial infarction (MI) and/or stroke in this post hoc analysis of data from the LEADER trial. Participants of the LEADER trial included 9,340 patients with type 2 diabetes and high cardiovascular risk who were randomized to receive either 1.8 mg (or maximum tolerated dose) of liraglutide or placebo and were followed up for a median of 3.8 years. MI/stroke history was noted among 3,692 (39.5%) patients, atherosclerotic cardiovascular disease without MI/stroke in 3,083 (33.0%), and 2,565 (27.5%) patients were noted to have risk factors only. Patients with a history of MI/stroke and those with established atherosclerotic cardiovascular disease without MI/stroke showed reduced cardiovascular outcomes on receiving liraglutide. In patients with cardiovascular risk factors alone, the cardiovascular effect appeared neutral.